-
The French Guiana-Martinique submarine cable is scheduled to start production at the end of the month
Time of Update: 2023-01-01
Telecommunications giant Orange Group has announced the official completion of its wholly-owned Kanawa submarine cable system connecting French Guiana and Martinique, with a total investment of 35 million euros.
-
The Codex Alimentarius Commission issues new guidelines to pave the way for the mass production of ready-to-use therapeutic foods
Time of Update: 2022-12-29
"WHO is pleased that the Codex Alimentarius Commission has developed guidelines for ready-to-use therapeutic foods, providing clear standards for this product, which will drive the current discussion on the inclusion of ready-to-use therapeutic foods in the list of essential medicines, with more children expected to benefit as ready-to-use therapeutic foods enter national programmes to treat severe acute malnutrition," explained Jaden Bendabunda, WHO Technical Officer.
-
The Australia-Singapore-Indonesia submarine cable INDIGO is expected to be completed ahead of schedule
Time of Update: 2022-12-28
Submarine cables According to the plan, the Pace landing will be completed in early September and land in Sydney in mid-October, with a final merger of INDIGO-Central in early December this year.
-
The upgrading trend of the pharmaceutical equipment industry will be more automated, digital and intelligent
Time of Update: 2022-11-04
In November of the same year, the Notice on Promoting the High-quality Development of the API Industry Implementation Plan was issued, requiring the promotion of cross-field resource sharing and cooperation, strengthening the integration and cooperation between bioengineering, fine chemicals, hazardous waste disposal, pharmaceutical equipment and API enterprises, and improving the modernization level of the industrial chain.
-
The team of Xu Yikai of Nanfang Hospital has published a series of new results in internationally renowned academic journals
Time of Update: 2022-11-04
Recently, the research results of Professor Xu Yikai's team in the field of tumor molecular imaging and functional imaging of Nanfang Hospital have been published online in internationally renowned j
-
Attention should be paid to differentiating benign paroxysmal positional vertigo from vestibular migraine
Time of Update: 2022-10-25
Benign paroxysmal positional vertigo (BPPV) and vestibular migraine (VM) are different independent diseases with completely different treatment methods and the choice of treatment modality affects eff
-
Hengmei high intelligent food safety detector - to ensure food quality and safety
Time of Update: 2022-10-20
Hengmeigao intelligent food safety detector adopts advanced fast inspection technology, quickly screens out unqualified food, the instrument is equipped with Android intelligent operating system, integrated host includes food safety detection module, multi-functional pesticide residue detection module, colloidal gold immunochromatographic detection module, multiple detection functions, complete testing items.
-
Another new drug withdrew its drug registration application
Time of Update: 2022-08-15
Buchang Pharmaceutical announced on the evening of May 9 that due to the need to further improve the application materials for fasudil hydrochloride injection, after careful research and decision, Tonghua Guhong applied to the State Food and Drug Administration to withdraw the drug registration of fasudil hydrochloride injection apply .
-
Local pharmaceutical companies are accelerating innovation and transformation, and competition is becoming increasingly fierce
Time of Update: 2022-05-08
From the perspective of pharmaceutical companies that have disclosed R&D investment data, local pharmaceutical companies are accelerating the pace of innovation and transformation .
The R&D investment of Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, CSPC and other companies has exceeded 3 billion yuan on average, reaching 6.
-
The FGFR inhibitor introduced by Express Innovent Bio was approved in mainland China for the treatment of cholangiocarcinoma
Time of Update: 2022-04-25
▎WuXi AppTec content team reported that on April 6, the official website of the China National Medical Products Administration (NMPA) announced that the FGFR1/2/3 inhibitor pemigatinib introduced by Innovent Biotech from Incyte has been approved listed .
-
Headache treats the head, foot pain treats the foot, stomach pain treats the stomach
Time of Update: 2022-03-02
The patient's blood routine showed anemia, thrombocytopenia, and the proportion and absolute value of monocytes increased significantly.
Criteria, excluding other causes of mononucleosis, and because the patient's blood film showed Auer bodies, the final diagnosis should be CMML-2 .
-
[Crisis event] Sudden supine hypotension syndrome during perianesthesia
Time of Update: 2022-02-24
3. The symptoms of sudden supine hypotension syndrome during the peri-anesthesia period Hypotensive shock-related symptoms that occurred after pregnant women in the third trimester of pregnancy were supine for several minutes: dizziness, chest tightness, nausea, vomiting, whole body cold sweat, rapid pulse, systolic blood pressure decreased by 30mmHg or Drop to below 80mmHg; hypotension can cause acute fetal distress: increased fetal heart rate, increased fetal movement, followed by slow fetal heart rate and weakened fetal movement .
-
Within two days, a pharmaceutical company spent huge sums of money to introduce a number of new technologies one after another
Time of Update: 2022-01-23
Under the agreement, Pfizer paid Dren Bio an upfront payment of $25 million, while the company is also eligible to receive development, regulatory and commercialization milestone payments totaling more than $1 billion .
-
The investigative Alzheimer's disease treatment LECANEMAB was designated by the U.S. FDA for fast-track application
Time of Update: 2022-01-09
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
The title of breakthrough therapy and the fast-track application designation are two FDA plans to promote and accelerate the development of new drugs to meet those unmet medical needs (for example: Alzheimer's disease) for the treatment of serious or life-threatening diseases Disease and provide opportunities for frequent interaction with the FDA .
-
Hengrui Medicine's new generation of PARP inhibitor fluzoparib (Irei®) is included in the new version of the National Medical Insurance Catalogue in 2021
Time of Update: 2021-12-31
Hengrui Pharmaceuticals independently developed a category 1 innovative drug and China's first original PARP inhibitor fluzoparib successfully entered the new version of the medical insurance catalog .
